Pfizer And Ionis’s Antisense Cholesterol Candidate Sparks Safety Worries
Concerns Despite Phase IIb Win
Increases in liver enzymes and fat could dampen approval prospects despite vupanorsen meeting its mid-stage primary endpoint, some analysts have said.
You may also be interested in...
Evkeeza is the first ANGPTL3 approved by the FDA; Regeneron scientists discovered the angiopoetin gene family.
The Italian company will acquire EUSA for €750m, helping to broaden its rare disease franchise into the oncology arena.
The firm’s sole nephrological asset has demonstrated proof of concept, helping advance the novel gene-targeted therapy into pivotal development early next year.